The Full Year Statutory Accounts tell you a couple of important things:
1. Bionomics has debt that essentially matches its cash and receivables.
2. Bionomics plans another mindless clinical trial for BNC 210.
Message that is not in bold type: There is a highly dilutive capital raising coming very soon and it will be at a big discount to the current share price because whoever has risk appetite will expect the offer to be very attractive, given the risks of losing the lot.
When the penny drops, 3.7c will seem like a good price to walk away.........
I hope all readers had a real good look at the money that walked out the door with the Directors, former executives and other leaches.
The place is a retirement village for the enrichment of has-been crocks that have nothing to offer........
Stick around at your peril.
BNO Price at posting:
3.7¢ Sentiment: Sell Disclosure: Not Held